CAR-T cell therapies have reshaped the treatment paradigm for hematological cancers, relying on lentiviral vectors (LVVs) to deliver Chimeric Antigen Receptor (CAR) genes into patient T cells. As clinical success drives increasing demand, manufacturers face growing pressure to scale LVV production efficiently while maintaining high titers and controlling costs. Yet, commercial-scale manufacturing remains challenging due to high dose requirements, low downstream yields, lengthy process development timelines, and elevated Cost of Goods per dose.
This application note explores how the scale-X™ fixed-bed bioreactor platform enables rapid process transfer and scalable LVV production for an approved CAR-T therapy. By combining adherent cell culture, high cell density, and perfusion capabilities within a compact, automation-ready system (0.5–600 m² growth area), the platform supports seamless transition from traditional 2D systems to GMP-ready manufacturing scale.
Discover how, within just 8 months, LVV production was:
- Successfully transferred from T-flasks to the scale-X™ hydro bioreactor (2.4 m²)
- Scaled up to the scale-X™ carbo bioreactor (10 m²)
- Maintained at high titers throughout scale-up
- Optimized to achieve a 40% reduction in Cost of Goods per dose
Learn how this intensified, automated, and scalable approach not only reduces manufacturing costs but also enhances batch consistency, minimizes manual interventions, lowers contamination risk, and accelerates the path to commercial availability – ultimately contributing to more accessible, life-saving CAR-T therapies.